- Home
- Our company
- Code of Business Conduct
Code of
Business Conduct
At Johnson & Johnson, we believe acting ethically and responsibly is not only the right thing to do, but also the right thing to do for our business. Our Johnson & Johnson Code of Business Conduct ensures that we hold ourselves and how we do business to a high standard, allowing us to fulfill our obligations to the many stakeholders we serve.
Effective May 16, 2024, Johnson & Johnson amended its Code of Business Conduct to provide enhanced guidance on addressing the evolving business environment, reflecting our commitment to compliance and responsible operations.
Effective May 16, 2024, Johnson & Johnson amended its Code of Business Conduct to provide enhanced guidance on addressing the evolving business environment, reflecting our commitment to compliance and responsible operations.
Our Credo Integrity Line
Our Credo Integrity Line is an integral component of our strong culture of integrity at Johnson & Johnson. It provides a channel for anyone (including employees, business partners, customers, consumers and others) to report potential violations of the Code of Business Conduct, other company policies or applicable laws and regulations in our countries of operation. Our Credo Integrity Line is available 24 hours a day, 7 days a week and in 24 languages.
Go to the Our Credo Integrity Line website for more information including directions for filing concerns digitally or by phone.
Go to the Our Credo Integrity Line website for more information including directions for filing concerns digitally or by phone.
Additional policies & resources
The values and principles spelled out in Our Credo serve as our compass; the Johnson & Johnson Code of Business Conduct is the road map that helps us stay on course with those values. The Code sets requirements for business conduct and serves as a foundation for our Company policies, procedures and guidelines, all of which provide additional guidance on expected behaviors.
Our Credo
The values that guide our decision-making are spelled out in Our Credo. Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.
Robert Wood Johnson, former chairman from 1932 to 1963 and a member of the Company’s founding family, crafted Our Credo himself in 1943, just before Johnson & Johnson became a publicly traded company. This was long before anyone ever heard the term “corporate social responsibility.” Our Credo is more than just a moral compass. We believe it’s a recipe for business success. The fact that Johnson & Johnson is one of only a handful of companies that have flourished through more than a century of change is proof of that.
Robert Wood Johnson, former chairman from 1932 to 1963 and a member of the Company’s founding family, crafted Our Credo himself in 1943, just before Johnson & Johnson became a publicly traded company. This was long before anyone ever heard the term “corporate social responsibility.” Our Credo is more than just a moral compass. We believe it’s a recipe for business success. The fact that Johnson & Johnson is one of only a handful of companies that have flourished through more than a century of change is proof of that.
Policies and reports
The print and digital publications we produce each year that recap the company’s business performance and key enterprise-wide milestones.
More from Johnson & Johnson
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
6 ways Johnson & Johnson is using AI to help advance healthcare
Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.
How Johnson & Johnson is advancing the fight against Alzheimer’s disease
After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.